

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

NMPA Approval for Registration Application of Tethys AS® Aspiration Catheter

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on May 20, 2022, the Group received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局) (the “**NMPA**”) for the registration application of Tethys AS® Aspiration Catheter, making it the Group’s twelfth NMPA approved neurointerventional product.

Tethys AS® Aspiration Catheter is an acute ischemic stroke (“**AIS**”) revascularization product developed by Achieva Medical (“**Achieva**”), a wholly-owned subsidiary of the Company. The product provides an effective solution for thrombus removal, featuring a wide lumen and easy positioning. The 0.071-inch wide lumen of Tethys AS® Aspiration Catheter largely increases the aspiration force, which can significantly shorten the procedure time. It features a longer soft segment at the distal end, which conforms to the tortuous vessels and largely enhances its deliverability to the distal vessels. The optimized design of the transitional structure improves the trackability of the catheter, allowing the device to be delivered to the target vessel more easily. The entire device adopts a double-layer design with outer braids and inner coils, which allows high compressive strength and helps maintain lumen integrity. Tethys AS® aspiration catheter is available in 2 inner diameters and 4 effective lengths, with 14 different models in total. Physicians can select a proper model based on their preferences and the clinical manifestations of patients.

According to a number of high-quality clinical studies, direct aspiration has become as a first line treatment technique for patients with AIS. As of this date, Achieva offers treatment solutions including both aspiration and stent retriever thrombectomy for AIS patients. Its product lines cover a number of devices, including Tethys AS[®] Aspiration Catheter, Syphonet[®] Stent Retriever, Tethys[®] Intermediate Catheter, Presgo[®] Micro Guidewire, Presgo[®] Microcatheter, and Fluxcap[®] Balloon Guiding Catheter (to be approved), to address the clinical needs in mechanical thrombectomy. Achieva will continue to enrich the product deployment in the aspect of ischemic stroke, facilitate the construction of domestic stroke centers and popularize the interventional treatment of ischemic stroke patients.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET Tethys AS[®] ASPIRATION CATHETER SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, May 22, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.